ArticlePloS one2017
A multivariate predictive modeling approach reveals a novel CSF peptide signature for both Alzheimer's Disease state classification and for predicting future disease progression.
Article in PloS one, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 33 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
33 citing papers in PubMed, 1 synthesis or guideline pooled it, 55 citations in OpenAlex.
- Systematic Review: microRNAs as Potential Biomarkers in Mild Cognitive Impairment Diagnosis.Frontiers in aging neuroscience · 2021Pooled it
- VGF Peptides in Cerebrospinal Fluid of Patients with Dementia with Lewy Bodies.International journal of molecular sciences · 2019Trial
- Discovery of an ApoE4-targeted small-molecule SirT1 enhancer for the treatment of Alzheimer's disease.Scientific reports · 2025Article
- Probe-dependent Proximity Profiling (ProPPr) Uncovers Similarities and Differences in Phospho-Tau-Associated Proteomes Between Tauopathies.Molecular neurodegeneration · 2025Article
- Predicted natural progression as an Alzheimer's prognostic covariate improves the precision of lecanemab efficacy assessments and clinical trial efficiency.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2025Article
- Serum metabolome profiling in patients with mild cognitive impairment reveals sex differences in lipid metabolism.bioRxiv : the preprint server for biology · 2024Article
- Predicting clinical progression trajectories of early Alzheimer's disease patients.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2024Article
- Distinct CSF biomarker-associated DNA methylation in Alzheimer's disease and cognitively normal subjects.Alzheimer's research & therapy · 2023Article
- Distinct CSF biomarker-associated DNA methylation in Alzheimer's disease and cognitively normal subjects.Research square · 2023Article
- Improving the Robustness of Variable Selection and Predictive Performance of Regularized Generalized Linear Models and Cox Proportional Hazard Models.Mathematics (Basel, Switzerland) · 2023Article
- Diagnostic accuracy study of automated stratification of Alzheimer's disease and mild cognitive impairment via deep learning based on MRI.Annals of translational medicine · 2022Article
- Neuronal pentraxins as biomarkers of synaptic activity: from physiological functions to pathological changes in neurodegeneration.Journal of neural transmission (Vienna, Austria : 1996) · 2022Review
- Review
- Association of peripheral blood DNA methylation level with Alzheimer's disease progression.Clinical epigenetics · 2021Article
- Mitochondrial impairments in aetiopathology of multifactorial diseases: common origin but individual outcomes in context of 3P medicine.The EPMA journal · 2021Review
- Mitochondriopathies as a Clue to Systemic Disorders-Analytical Tools and Mitigating Measures in Context of Predictive, Preventive, and Personalized (3P) Medicine.International journal of molecular sciences · 2021Review
- VGF as a biomarker and therapeutic target in neurodegenerative and psychiatric diseases.Brain communications · 2021Review
- APOE4 Copy Number-Dependent Proteomic Changes in the Cerebrospinal Fluid.Journal of Alzheimer's disease : JAD · 2021Article
- Multiscale causal networks identify VGF as a key regulator of Alzheimer's disease.Nature communications · 2020Article
- Neuronal pentraxin 2: a synapse-derived CSF biomarker in genetic frontotemporal dementia.Journal of neurology, neurosurgery, and psychiatry · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 2 institutions in 1 country.
Funding
Abstract
To determine if a multi-analyte cerebrospinal fluid (CSF) peptide signature can be used to differentiate Alzheimer's Disease (AD) and normal aged controls (NL), and to determine if this signature can also predict progression from mild cognitive impairment (MCI) to AD, analysis of CSF samples was done on the Alzheimer's Disease Neuroimaging Initiative (ADNI) dataset. The profiles of 320 peptides from baseline CSF samples of 287 subjects over a 3-6 year period were analyzed. As expected, the peptide most able to differentiate between AD vs. NL was found to be Apolipoprotein E. Other peptides, some of which are not classically associated with AD, such as heart fatty acid binding protein, and the neuronal pentraxin receptor, also differentiated disease states. A sixteen-analyte signature was identified which differentiated AD vs. NL with an area under the receiver operating characteristic curve of 0.89, which was better than any combination of amyloid beta (1-42), tau, and phospho-181 tau. This same signature, when applied to a new and independent data set, also strongly predicted both probability and rate of future progression of MCI subjects to AD, better than traditional markers. These data suggest that multivariate peptide signatures from CSF predict MCI to AD progression, and point to potentially new roles for certain proteins not typically associated with AD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.